Self-Management Data and Disease Progression in Chronic Kidney Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19-84
SponsorChungnam National University Hospital
About this trial
This study evaluates disease progression and management characteristics in patients with chronic kidney disease (CKD) using an integrated mobile application and hospital information system (HIS) clinical data.
The main goals of this study are:
1. To observe patient self-management recording performance and adherence (continuity of recording blood pressure, blood glucose, medication, and diet). 2. To explore associations between integrated self-management data and disease progression or acute exacerbations (e.g., acute kidney injury, hyperkalemia). 3. To gather foundational evidence for optimizing and improving future digital health applications for CKD management.
Participants will be recruited from outpatient clinics at Chungnam National University Hospital and followed prospectively for 1 year with regular follow-up visits.
Eligibility criteria
Qualifiers
Adult patients aged 19 years or older and under 85 years.
Patients visiting the hospital for chronic kidney disease (CKD) management.
Patients diagnosed with CKD or identified as high-risk for CKD requiring continuous management (e.g., diabetes mellitus, hypertension, proteinuria, or decreased eGFR).
Patients capable of recording self-management data (blood pressure, diet, medication) independently or with assistance through the provided mobile application.
Disqualifiers
Patients who do not sign the informed consent form or lack the capacity to fully understand the study protocol and express voluntary consent.
Patients currently undergoing maintenance dialysis (hemodialysis or peritoneal dialysis) for end-stage kidney disease (ESKD).
Patients deemed unsuitable for participation in the study by the investigator.
Trial design
Treatments tested in this trial
- CKD Self-Management Mobile Application
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov